Edward Rebar | Senior Vice President And Chief Technology Officer
Sangamo Therapeutics

Edward Rebar, Senior Vice President And Chief Technology Officer, Sangamo Therapeutics

Edward Rebar, has served as Senior Vice President and Chief Technology Officer since July 2018. Dr. Rebar joined Sangamo in 1998, and over the last 20 years has led the development of the Company's zinc finger protein technology platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley. 

Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.


Conference Day 2: Friday 17th May 2019 @ 08:40

Keynote presentation: Gene editing therapeutics

Conference Day 2: Friday 17th May 2019 @ 09:00

Keynote panel discussion: Exploring advances in gene editing technology, therapeutics and research

· Best strategies for implementing new methods across the field of clinical research, now and for the future· Optimisation of the delivery of gene editing technology, · How to minimise off-target effects and mutations for the safe and effective delivery of gene editing technology· Discussion of ethical and regulatory challenges, current legislation, how to navigate ethical concerns in light of the growing scale of genome editing. Most recently the CRISPR babies that were born in 2018
last published: 16/Apr/19 17:05 GMT

back to speakers